Literature DB >> 35201894

Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.

Neal A Patel1, Robert E Reiter1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35201894      PMCID： PMC9061148          DOI： 10.1200/JCO.21.02940

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  10 in total

1.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Authors:  Marlon Perera; Nathan Papa; Matthew Roberts; Michael Williams; Cristian Udovicich; Ian Vela; Daniel Christidis; Damien Bolton; Michael S Hofman; Nathan Lawrentschuk; Declan G Murphy
Journal:  Eur Urol       Date:  2019-02-14       Impact factor: 20.096

2.  Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.

Authors:  Heiko Schöder; Thomas A Hope; Michael Knopp; William K Kelly; Jeff M Michalski; Seth P Lerner; Abdul Tawab-Amiri; Bhupinder S Mann; Daniel W Lin; Evan Y Yu; Ronald C Chen; Gillian C Beach; Steven A Reeves; Lalitha K Shankar
Journal:  J Clin Oncol       Date:  2022-01-11       Impact factor: 50.717

Review 3.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.

Authors:  Matthias Eiber; Wolfgang P Fendler; Steven P Rowe; Jeremie Calais; Michael S Hofman; Tobias Maurer; Sarah M Schwarzenboeck; Clemens Kratowchil; Ken Herrmann; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

4.  Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Authors:  Jeremie Calais; Wolfgang P Fendler; Matthias Eiber; Jeannine Gartmann; Fang-I Chu; Nicholas G Nickols; Robert E Reiter; Matthew B Rettig; Leonard S Marks; Thomas E Ahlering; Linda M Huynh; Roger Slavik; Pawan Gupta; Andrew Quon; Martin S Allen-Auerbach; Johannes Czernin; Ken Herrmann
Journal:  J Nucl Med       Date:  2017-12-14       Impact factor: 10.057

5.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

6.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

Review 7.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.

Authors:  A M Hövels; R A M Heesakkers; E M Adang; G J Jager; S Strum; Y L Hoogeveen; J L Severens; J O Barentsz
Journal:  Clin Radiol       Date:  2008-02-04       Impact factor: 2.350

8.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Authors:  Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Robert R Flavell; Ashley Mishoe; Felix Y Feng; Hao G Nguyen; Robert E Reiter; Matthew B Rettig; Shozo Okamoto; Louise Emmett; Helle D Zacho; Harun Ilhan; Axel Wetter; Christoph Rischpler; Heiko Schoder; Irene A Burger; Jeannine Gartmann; Raven Smith; Eric J Small; Roger Slavik; Peter R Carroll; Ken Herrmann; Johannes Czernin; Thomas A Hope
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

9.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

10.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

Authors:  Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy
Journal:  Lancet       Date:  2020-03-22       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.